RVX-208 a Selective Bromodomain and Extra-terminal BET Protein Inhibitor Acts on Several Pathways to Benefit Cardiovascular Risks

被引：0
|
作者：
Wong, Norman C.
Kulikowski, Ewelina
Wasiak, Sylwia
Gilham, Dean
Halliday, Christopher
Lebioda, Kenneth
Sweeney, Mike
Johansson, Jan
机构：
来源：
CIRCULATION | 2015年 / 132卷
关键词：
Epigenetics; Inflammation; Complement HDL; Acute phase reactants;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
17127
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors
    Li, Yangfeng
    Shen, Zhengnan
    Ratia, Kiira
    Zhao, Jiong
    Huang, Fei
    Dubrovyskyii, Oleksii
    Indukuri, Divakar
    Fu, Jiqiang
    Ramos, Omar Lozano
    Thatcher, Gregory R. J.
    Xiong, Rui
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (04) : 2712 - 2731
  • [42] The Bromodomain and Extra-Terminal Protein Inhibitor OTX015 Suppresses T Helper Cell Proliferation and Differentiation
    Hu, Xiao
    Schewitz-Bowers, Lauren P.
    Lait, Philippa J. P.
    Copland, David A.
    Stimpson, Madeleine L.
    Li, Jing Jing
    Liu, Yizhi
    Dick, Andrew D.
    Lee, Richard W. J.
    Wei, Lai
    CURRENT MOLECULAR MEDICINE, 2018, 18 (09) : 594 - 601
  • [43] Rational therapeutic combination of Bromodomain and Extra-Terminal domain (BET) inhibitor and Fibroblast Growth Factor Receptor (FGFR) inhibitor for treatment of invasive lobular carcinoma
    Gao, Binbin
    Ward, Elspeth
    Blumel, Anna
    Conroy, Emer
    Moore, Rachel
    Cremin, Grainne
    Bleach, Rachel
    Haley, Kathryn
    Ni Chonghaile, Triona
    Lindner, Andreas
    Lindner, Andreas
    Prehn, Jochen
    Zhang, Yi
    Cruz, Idalia
    Hilakivi-Clarke, Leena
    Sflomos, Georgios
    Brisken, Cathrin
    Gallagher, William
    O'Connor, Darran
    CANCER RESEARCH, 2024, 84 (09)
  • [44] The BET protein inhibitor apabetalone (RVX-208) restores angiogenic response in type 1 and type 2 diabetes by transcriptional regulation of thrombospondin-1
    Mohammed, S.
    Mattia, M. A.
    Gergely, G. K.
    Gaia, G. S.
    Ambrosini, S. A.
    Paolo, P. M.
    Thomas, T. F. L. F.
    Sarah, S. C.
    Paolo, G. P. F. Gian
    Francesco, F. P.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3384 - 3384
  • [45] Bromodomain and Extra-Terminal Protein inhibition decreases pancreatic cancer proliferation via MYC-independent pathways.
    Rana, Manjul
    Kansal, Rita G.
    Fang, Jie
    Allen, Benjamin T.
    Yang, Jun
    Glazer, Evan S.
    CANCER RESEARCH, 2022, 82 (22) : 86 - 87
  • [46] Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design
    Gavai, Ashvinikumar, V
    Norris, Derek
    Delucca, George
    Tortolani, David
    Tokarski, John S.
    Dodd, Dharmpal
    O'Malley, Daniel
    Zhao, Yufen
    Quesnelle, Claude
    Gill, Patrice
    Vaccaro, Wayne
    Tram Huynh
    Ahuja, Vijay
    Han, Wen-Ching
    Mussari, Christopher
    Harikrishnan, Lalgudi
    Kamau, Muthoni
    Poss, Michael
    Sheriff, Steven
    Yan, Chunhong
    Marsilio, Frank
    Menard, Krista
    Wen, Mei-Li
    Rampulla, Richard
    Wu, Dauh-Rurng
    Li, Jianqing
    Zhang, Huiping
    Li, Peng
    Sun, Dawn
    Yip, Henry
    Traeger, Sarah C.
    Zhang, Yingru
    Mathur, Arvind
    Zhang, Haiying
    Huang, Christine
    Yang, Zheng
    Ranasinghe, Asoka
    Everlof, Gerry
    Raghavan, Nirmala
    Tye, Ching Kim
    Wee, Susan
    Hunt, John T.
    Vite, Gregory
    Westhouse, Richard
    Lee, Francis Y.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14247 - 14265
  • [47] Use of structure-based design in the discovery of the BCL-2 selective inhibitor Venclexta® and the bromodomain and extra-terminal domain (BET) inhibitors mivebresib and ABBV-744
    Hasvold, Lisa
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [48] Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression
    Jones, Katherine L.
    Beaumont, Dominic M.
    Bernard, Sharon G.
    Bit, Rino A.
    Campbell, Simon P.
    Chung, Chun-wa
    Cutler, Leanne
    Demont, Emmanuel H.
    Dennis, Kate
    Gordon, Laurie
    Gray, James R.
    Haase, Michael, V
    Lewis, Antonia J.
    McCleary, Scott
    Mitchell, Darren J.
    Moore, Susanne M.
    Parr, Nigel
    Robb, Olivia J.
    Smithers, Nicholas
    Soden, Peter E.
    Suckling, Colin J.
    Taylor, Simon
    Walker, Ann L.
    Watson, Robert J.
    Prinjha, Rab K.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (16) : 12200 - 12227
  • [49] Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
    Chan, Kwok-Ho
    Zengerle, Michael
    Testa, Andrea
    Ciulli, Alessio
    JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (02) : 504 - 513
  • [50] DOSE OPTIMIZATION OF MK-8628 (OTX015), A SMALL MOLECULE INHIBITOR OF BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Hottinger, A. F.
    Sanson, M.
    Moyal, E.
    Delord, J.
    Rezai, K.
    Leung, A.
    Perez, S.
    Bekradda, M.
    Lachaux, N.
    Chinot, O.
    NEURO-ONCOLOGY, 2016, 18 : 56 - 56
12345